SCIENTIFIC PUBLICATIONS

LATEST PUBLICATIONS

SOHO, Sept 4, 2024: CARDINAL: A Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Chronic Myeloid Leukemia

SOHO, Sept 4, 2024: Safety, Tolerability, Pharmacokinetics, and the Effect of Food on TERN-701, an Oral Allosteric BCR-ABL Tyrosine Kinase Inhibitor, in Healthy Participants

PAST PUBLICATIONS

ADA, Jun 21, 2024: TERN-501 Enhances Weight Loss Efficacy of a GLP-1R Agonist in Obese Mice via Increased Fat Mass Loss without Additional Loss of Lean Mass

EASL, Jun 8, 2024: TERN-501, a highly selective thyroid hormone receptor β agonist, significantly improved MRI-PDFF, cT1, and liver volume in clinically relevant patient populations with presumed MASH: subgroup analyses from a 12-week phase 2a trial

EASL, Jun 8, 2024: Sex hormone binding globulin as an effective predictor of treatment response to TERN-501, a potent, highly selective thyroid hormone receptor β agonist: post-hoc analyses from a 12-week phase 2a trial

AASLD, Nov 13, 2023: Topline Results from a 12-Week Phase 2a Trial (DUET) Evaluating TERN-501, a Highly Selective Thyroid Hormone Receptor (THR)β Agonist, Either as Monotherapy or in Combination with TERN-101, a Nonsteroidal Farnesoid X Receptor (FXR) Agonist, Demonstrated Significant Reductions in MR-Based Liver Fat Content and Fibroinflammation in Patients with Presumed MASH

AASLD, Nov 11, 2023: A Stepwise Screening Approach Using Noninvasive Tests To Identify Phenotypic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients With Fibrosis For Clinical Trials

SOHO, September 6, 2023: The novel BCR::ABL1 allosteric inhibitor TERN-701 (HS-10382) is potent against mutations resistant to active site tyrosine kinase inhibitors (TKIs) and acts synergistically with TKIs in BCR::ABL1+ cancer cell lines

EASL, June 24, 2023: A stepwise screening approach using noninvasive tests to identify phenotypic nonalcoholic steatohepatitis (NASH) patients with fibrosis for clinical trials

EASL, June 21, 2023: Combination therapy of TERN-501, a selective agonist of thyroid hormone receptor (THR) beta, with TERN-101, a Farnesoid X receptor (FXR) agonist, improves nonalcoholic steatohepatitis (NASH) in the GAN diet-induced obese and biopsy-confirmed mouse model

ASCO, June 5th, 2023: A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10382 (TERN-701) in patients (pts) with chronic myeloid leukemia (CML)

ASPET, May 18th, 2023: Efficacy of HS-10382 (TERN-701) in tumor xenograft models, a new investigational allosteric ABL1 kinase inhibitor as a potential treatment for CML

AASLD, November 5, 2022: Thyroid Hormone Beta Receptor Agonist TERN-501 Demonstrates Dose- and Exposure-Dependent Increases in Sex Hormone Binding Globulin with Associated Decreases in Atherogenic Lipids in Healthy Subjects

AASLD, November 5, 2022: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Phase 2a Study with Factorial Design to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of TERN-501 Alone and in Combination with TERN-101 in Patients with NASH

Presentation: Multiple doses of thyroid hormone receptor-beta agonist TERN-501 were well-tolerated and resulted in significant dose-dependent changes in serum lipids and sex hormone binding globulin in a first-in-human clinical study

Poster: Favorable lipid and pruritus profile of liver-distributed farnesoid X receptor agonist TERN-101 at clinically efficacious doses in nonalcoholic steatohepatitis phase 2a LIFT study

Poster: Liver-distributed farnesoid X receptor agonist TERN-101 demonstrates potent target engagement with a favorable exposure-response profile in nonalcoholic steatohepatitis patients

Poster: TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in nonalcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study

Poster: Favorable safety profile of TERN-201, a highly selective inhibitor of vascular adhesion protein-1, in the nonalcoholic steatohepatitis phase 1b AVIATION study

AASLD, November 14, 2021: Liver-distributed FXR Agonist TERN-101 Demonstrates Favorable Safety and Efficacy Profile in NASH Phase 2a LIFT Study

AASLD, November 12, 2021: Liver-distributed FXR Agonist TERN-101 Leads to Corrected T1 (cT1) Response and a Population Shift to Lower cT1 Risk Categories in NASH Phase 2a LIFT Study

AASLD, November 12, 2021: Single Doses of the THR-β Agonist TERN-501 are Well Tolerated and Result in Dose-dependent Changes in LDL Cholesterol and Sex Hormone Binding Globulin in a First-in-Human Clinical Trial

NASH-TAG, March 13, 2021: Targeting VAP-1 Inhibition in NASH

NASH-TAG, March 11, 2021: Liver-distributed Farnesoid X Receptor agonist TERN-101 is more efficacious in a mouse model of non-alcoholic steatohepatitis than Obeticholic Acid

AASLD, November 13, 2020: TERN-101, a liver selective FXR agonist, is well-tolerated, and produces potent 7α-C4 reductions and FGF19 increases with no pruritis in healthy participants

AASLD, November 13, 2020: Combination of TERN-101, a farnesoid X receptor agonist, and TERN-501, a selective agonist of thyroid hormone receptor beta, reduces activation of inflammatory and fibrotic gene pathways in a mouse model of non-alcoholic steatohepatitis

AASLD, November 13, 2020: Multiple ascending doses of TERN-201, a novel selective semicarbazide-sensitive amine oxidase (SSAO) inhibitor, fully suppresses plasma SSAO activity in a Phase 1 study

AASLD, November 13, 2020: Pharmacokinetics and Tissue Distribution of TERN-201, a Novel Investigational SSAO/VAP-1 Inhibitor, in Preclinical Species

PARIS NASH Meeting, October 22, 2020: Pharmacokinetics of two oral formulations of liver-directed, nonsteroidal farnesoid x-receptor agonist tern-101 in healthy volunteers  

EASL, August 28, 2020: Single doses of TERN-201, a novel selective semicarbazide-sensitive amine oxidase (SSAO) inhibitor, are safe, well-tolerated, and result in sustained reduction of SSAO activity in healthy participants

EASL, August 29, 2020: Anti-inflammatory and anti-fibrotic activity of TERN-201, a semicarbazide-sensitive amine oxidase inhibitor, in a rat choline-deficient high-fat diet non-alcoholic steatohepatitis model

EASL, August 29, 2020:  TERN-501, a potent and selective agonist of thyroid hormone receptor beta, strongly reduces histological features and biomarkers of non-alcoholic steatohepatitis associated pathology in rodent models    

The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease

NASH-TAG, January 10, 2020: Single Doses of TERN-201, a Novel Selective Semicarbazide-sensitive Amine Oxidase (SSAO) Inhibitor, are Safe, Well-tolerated, and Result in Reduced Plasma SSAO Activity in Healthy Participants

AASLD, October 15, 2019: Pharmacokinetics, Tissue Distribution and Pharmacodynamics of TERN-101, A Novel Farnesoid X Receptor (FXR) Agonist, in Preclinical Species

EASL, April 12, 2019: A Novel Farnesoid X Receptor Agonist, TERN-101, Reduces Liver Steatosis, Inflammation, Ballooning and Fibrosis in a Murine Model of Non-alcoholic Steatohepatitis

EASL, April 12, 2019: A Novel Semicarbazide-sensitive Amine Oxidase Inhibitor, TERN-201, Reduces NAS and Fibrosis in Rodent Models of Non-alcoholic Steatohepatitis